Theravance Biopharma Stock Total Debt
| TBPH Stock | USD 9.46 0.09 0.96% |
Theravance Biopharma fundamentals help investors to digest information that contributes to Theravance Biopharma's financial success or failures. It also enables traders to predict the movement of Theravance Stock. The fundamental analysis module provides a way to measure Theravance Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Theravance Biopharma stock.
The current Total Debt To Capitalization is estimated to decrease to 0.18. Theravance | Total Debt |
Theravance Biopharma Company Total Debt Analysis
Theravance Biopharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Theravance Biopharma Total Debt | 45.24 M |
Most of Theravance Biopharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theravance Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Theravance Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Theravance Biopharma is extremely important. It helps to project a fair market value of Theravance Stock properly, considering its historical fundamentals such as Total Debt. Since Theravance Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Theravance Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Theravance Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Theravance Total Debt Historical Pattern
Today, most investors in Theravance Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Theravance Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Theravance Biopharma total debt as a starting point in their analysis.
Theravance Biopharma Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Theravance Long Term Debt
Long Term Debt |
|
Based on the latest financial disclosure, Theravance Biopharma has a Total Debt of 45.24 M. This is 98.36% lower than that of the Pharmaceuticals sector and 86.07% lower than that of the Health Care industry. The total debt for all United States stocks is 99.15% higher than that of the company.
Theravance Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theravance Biopharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics of similar companies.Theravance Biopharma is currently under evaluation in total debt category among related companies.
Theravance Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Theravance Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Theravance Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Theravance Biopharma's value.| Shares | Park West Asset Management Llc | 2023-12-31 | 900 K | D. E. Shaw & Co Lp | 689.6 K | Goldman Sachs Group Inc | 2023-12-31 | 572.6 K | Bank Of America Corp | 562.5 K | Northern Trust Corp | 2023-12-31 | 521.9 K | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 407.5 K | Jane Street Group, Llc | 2023-12-31 | 371.5 K | Charles Schwab Investment Management Inc | 2023-12-31 | 314 K | Chescapmanager Llc | 2023-09-30 | 287.3 K | Weiss Asset Management Lp | 2023-12-31 | 7.5 M | Baupost Group Llc | 2023-12-31 | 7.4 M |
Theravance Fundamentals
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.0673 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | (0.36) % | ||||
| Current Valuation | 398.04 M | ||||
| Shares Outstanding | 48.56 M | ||||
| Shares Owned By Insiders | 14.51 % | ||||
| Shares Owned By Institutions | 85.49 % | ||||
| Number Of Shares Shorted | 6.43 M | ||||
| Price To Earning | (6.20) X | ||||
| Price To Book | 2.19 X | ||||
| Price To Sales | 8.13 X | ||||
| Revenue | 57.42 M | ||||
| Gross Profit | (12.05 M) | ||||
| EBITDA | (40.28 M) | ||||
| Net Income | (55.19 M) | ||||
| Cash And Equivalents | 132.85 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 45.24 M | ||||
| Debt To Equity | 652.20 % | ||||
| Current Ratio | 4.74 X | ||||
| Book Value Per Share | 4.43 X | ||||
| Cash Flow From Operations | (27 M) | ||||
| Short Ratio | 14.32 X | ||||
| Earnings Per Share | (1.00) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 15.4 | ||||
| Number Of Employees | 99 | ||||
| Beta | 0.35 | ||||
| Market Capitalization | 455.01 M | ||||
| Total Asset | 382 M | ||||
| Retained Earnings | (909.1 M) | ||||
| Working Capital | 108.77 M | ||||
| Current Asset | 237.47 M | ||||
| Current Liabilities | 49.47 M | ||||
| Net Asset | 382 M |
About Theravance Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Theravance Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Theravance Biopharma's short interest history, or implied volatility extrapolated from Theravance Biopharma options trading.
Currently Active Assets on Macroaxis
| LAAC | Lithium Americas Corp | |
| F | Ford Motor | |
| CHPT | ChargePoint Holdings | |
| AXL | American Axle Manufacturing | |
| ICLN | iShares Global Clean |
Check out Theravance Biopharma Piotroski F Score and Theravance Biopharma Altman Z Score analysis. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.199 | Return On Assets (0.07) | Return On Equity (0.17) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.